The current FDA label for SPRYCEL (dasatinib) explicitly states:
“Do not administer H₂ antagonists or proton pump inhibitors with SPRYCEL. Consider the use of antacids in place of H₂ antagonists or proton pump inhibitors.”
It recommends antacids (if needed) be taken at least 2 hours before or after dasatinib, because simultaneous use still reduces exposure.
Clinical data cited in the label and supporting studies show clear reductions:
Omeprazole (40 mg) given ~22 hours before a 100 mg dasatinib dose reduced AUC by ~43% and Cₘₐₓ by ~42%.
Famotidine (H₂RA, but mechanistically similar) reduced AUC and Cₘₐₓ by 61% and 63%.
Real-world and controlled DDI studies report bioavailability reductions of 40–80% (some recent pharmacokinetic studies with precise pH control show even higher reductions, up to ~89–96% in worst-case timing).
This means a PPI can meaningfully lower the effective dasatinib dose you actually get into your bloodstream, potentially reducing efficacy (e.g., poorer disease control in CML or Ph+ ALL) unless the dose is adjusted or monitored therapeutically.
Newer dasatinib formulations (e.g., Phyrago™, XS004/Dasynoc, or amorphous solid-dispersion versions) were specifically developed to be pH-independent. These have minimal or no clinically significant interaction with PPIs and can be taken together. If you are on one of these, the answer changes. Always confirm which brand/formulation you have.
Alternatives if you need acid suppression: Use short-acting antacids (separated by ≥2 hours) instead of PPIs or H₂RAs. Some patients switch to H₂RAs with careful timing as you are doing, but the label still suggests avoiding them.
Clinical implication: Many real-world studies show PPI co-use with standard dasatinib is surprisingly common despite warnings and is linked to higher rates of treatment failure or need for dose escalation/monitoring.
Bottom line: For standard (Sprycel) dasatinib, yes — it “requires” gastric acid, and a PPI will reduce the effective dose. Talk to your oncologist or pharmacist about your specific formulation, possible therapeutic drug monitoring of dasatinib levels, or switching acid-suppression strategies. Be sure to discuss this with your doctor.
